Key clinical point: Venetoclax resulted in a good overall response rate (ORR) but short progression-free survival (PFS) in high-risk and heavily pretreated patients with relapsed/refractory mantle cell lymphoma (MCL).
Major finding : At a median follow-up of 16.4 months, patients receiving venetoclax without or with other agents had a median PFS and overall survival of 3.7 (95% CI 2.3-5.6) months and 12.5 (95% CI,6.2-28.2) months, respectively, and an ORR of 40%.
Study details: The data come from a multicenter retrospective study including 81 adult patients with relapsed/refractory MCL, most being heavily pretreated (median of three prior treatments) and having high-risk features including high Ki-67 and TP53 alterations, who received venetoclax without (n = 50) or with (n = 31) other agents.
Disclosures: This study was partly supported by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and others. Some authors reported ties with various organizations.
Source: Sawalha Y et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 (Feb 21). Doi: 10.1182/bloodadvances.2022008916